Discovery from the lab of Youyang Zhao, PhD, from Stanley Manne Children’s Research Institute at Ann & Robert H. Lurie Children’s Hospital of Chicago offers promising treatment approaches for acute respiratory distress syndrome (ARDS) in the elderly that can be caused by severe COVID-19, pneumonia, flu or sepsis.
Therapeutic nanocarriers engineered from adult skin cells can curb inflammation and tissue injury in damaged mouse lungs, new research shows, hinting at the promise of a treatment for lungs severely injured by infection or trauma.
Mechanisms involved in the rapid, severe progression of fibrosis in the lung tissues of COVID-19 patients, a potentially fatal complication of the virus that damages and scars the lungs, have been uncovered by researchers led by UTHealth Houston.
Article title: CD14-positive extracellular vesicles in bronchoalveolar lavage fluid as a new biomarker of acute respiratory distress syndrome Authors: Rahul Y. Mahida, Joshua Price, Sebastian T. Lugg, Hui Li, Dhruv Parekh, Aaron Scott, Paul Harrison, Michael A. Matthay, David R.…
A six country clinical study of more than 1,100 hospitalized COVID-19 patients who required high-flow nasal cannula oxygen therapy suggests that prone positioning (rotating patients with severe breathing issues so they are face down) soon after admission can significantly reduce the need for mechanical ventilation.
A new treatment is among the first known to reduce the severity of acute respiratory distress syndrome caused by the flu in animals, according to a new study.
An unfortunate truth about using mechanical ventilation to save lives is that the pressure can cause further lung damage. Scientists are working to boost a natural cellular process in pursuit of a therapy that could lower the chances for lung damage in patients on ventilators.
Researchers from the Morgridge Institute for Research, the University of Wisconsin-Madison, and Albany Medical College have identified more than 200 molecular features that strongly correlate with COVID-19 severity, offering insight into potential treatment options for those with advanced disease.
Researchers in France have discovered that patients suffering from severe COVID-19 show changes in a class of immune cells known as unconventional T cells. The study, published today in the Journal of Experimental Medicine (JEM), suggests that monitoring the activity of these cells in the blood of patients could predict the severity and course of the disease.
As COVID-19 continues to impact the world, health care professionals are finding more patients who were diagnosed with the illness but still are dealing with symptoms long after the initial infection has gone. This condition is sometimes referred to as “long COVID.”
Researchers at the George Washington University and Albert Einstein College of Medicine published a review in the journal Nitric Oxide suggesting that nitric oxide treatment can be pivotal in the fight against SARS-CoV-2.
A new Viewpoint article published online in the Annals of the American Thoracic Society examines ventilation and medication strategies that can help avoid psychological trauma for severe COVID-19 survivors treated for acute respiratory distress syndrome (ARDS) with mechanical ventilation.
While most children infected with the novel coronavirus have mild symptoms, a subset requires hospitalization and a small number require intensive care. A new report from pediatric anesthesiologists, infectious disease specialists and pediatricians at the Children’s Hospital at Montefiore (CHAM) and Albert Einstein College of Medicine, describes the clinical characteristics and outcomes of children hospitalized with COVID-19, during the early days of the pandemic.
Joe G. N. “Skip” Garcia, MD, an academic pulmonary physician-scientist describes a complication in COVID-19.
The first COVID-19 patient in Texas has been enrolled in a stem cell therapy clinical trial for acute respiratory distress syndrome (ARDS) at The University of Texas Health Science Center at Houston (UTHealth).
A team of physician-scientists at Beth Israel Deaconess Medical Center are now enrolling patients in a clinical trial to evaluate a common anti-clotting drug for the treatment of COVID-19-positive patients with ARDS. The newly launched trial follows a special report the team published in the Journal of Trauma and Acute Care Surgery that suggested the use of a drug called tPA could reduce deaths among patients with ARDS as a complication of COVID-19.
Changes in the lung microbiome may help predict how well critically ill patients will respond to care, according to new research published online in the American Thoracic Society’s American Journal of Respiratory and Critical Care Medicine.